BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate

Por Juszczynski, Przemyslaw, Kutok, Jeffery L., Li, Cheng, Mitra, Joydeep, Aguiar, Ricardo C. T., Shipp, Margaret A.
Publicado em 2006

BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8

Por Yan, Qingsheng, Xu, Rong, Zhu, Liya, Cheng, Xin, Wang, Zhe, Manis, John, Shipp, Margaret A.
Publicado em 2013

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

Por Hao, Yansheng, Chapuy, Bjoern, Monti, Stefano, Sun, Heather H., Rodig, Scott J., Shipp, Margaret A.
Publicado em 2014

BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response

Por Yan, Qingsheng, Dutt, Shilpee, Xu, Rong, Graves, Katherine, Juszczynski, Przemyslaw, Manis, John P., Shipp, Margaret A.
Publicado em 2009

Heat Shock Protein 90 is a Rational Therapeutic Target in Diffuse Large B-cell Lymphoma

Por Abramson, Jeremy S., Chen, Wen, Takahashi, Hidenobu, Juszczynski, Przemyslaw, Takeyama, Kunihiko, Kutok, Jeffery L., Shipp, Margaret A.
Publicado em 2008

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas

Por Polo, Jose M., Juszczynski, Przemyslaw, Monti, Stefano, Cerchietti, Leandro, Ye, Kenny, Greally, John M., Shipp, Margaret, Melnick, Ari
Publicado em 2007

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Post-transplant Lymphoproliferative Disorders: Implications for Targeted Therapy

Por Green, Michael R., Rodig, Scott, Juszczynski, Przemyslaw, Ouyang, Jing, Sinha, Papiya, O’Donnell, Evan, Neuberg, Donna, Shipp, Margaret A.
Publicado em 2012

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt

Por Juszczynski, Przemyslaw, Chen, Linfeng, O'Donnell, Evan, Polo, Jose M., Ranuncolo, Stella M., Dalla-Favera, Riccardo, Melnick, Ari, Shipp, Margaret A.
Publicado em 2009

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

Por Chen, Linfeng, Monti, Stefano, Juszczynski, Przemyslaw, Daley, John, Chen, Wen, Witzig, Thomas E., Habermann, Thomas M., Kutok, Jeffery L., Shipp, Margaret A.
Publicado em 2008

No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-Cell Lymphoma

Por Wu, David, Dutra, Bethany, Lindeman, Neal, Takahashi, Hidenobu, Takeyama, Kunihiko, Harris, Nancy L., Pinkus, Geraldine S., Longtine, Janina, Shipp, Margaret, Kutok, Jeffery L.
Publicado em 2009

Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated with PDCD1LG2 Copy Gain

Por Shi, Min, Roemer, Margaretha GM, Chapuy, Bjoern, Liao, Xiaoyun, Sun, Heather, Pinkus, Geraldine S., Shipp, Margaret A., Freeman, Gordon J., Rodig, Scott J.
Publicado no Am J Surg Pathol (2014)

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas

Por Duan, Shanshan, Cermak, Lukas, Pagan, Julia K., Rossi, Mario, Martinengo, Cinzia, di Celle, Paola Francia, Chapuy, Bjoern, Shipp, Margaret, Chiarle, Roberto, Pagano, Michele
Publicado em 2012

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

Por Yoshihama, Sayuri, Roszik, Jason, Downs, Isaac, Meissner, Torsten B., Vijayan, Saptha, Chapuy, Bjoern, Sidiq, Tabasum, Shipp, Margaret A., Lizee, Gregory A., Kobayashi, Koichi S.
Publicado no Proc Natl Acad Sci U S A (2016)

The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

Por Juszczynski, Przemyslaw, Ouyang, Jing, Monti, Stefano, Rodig, Scott J., Takeyama, Kunihiko, Abramson, Jeremy, Chen, Wen, Kutok, Jeffery L., Rabinovich, Gabriel A., Shipp, Margaret A.
Publicado em 2007

Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B cell lymphoma distinguishes these tumor types fr...

Por Kondratiev, Svetlana, Duraisamy, Sekhar, Unitt, Christine L., Green, Michael R., Pinkus, Geraldine, Shipp, Margaret A., Kutok, Jeffery L., Drapkin, Ronny I., Rodig, Scott J.
Publicado em 2011

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas

Por Kluk, Michael J., Chapuy, Bjoern, Sinha, Papiya, Roy, Alyssa, Cin, Paola Dal, Neuberg, Donna S., Monti, Stefano, Pinkus, Geraldine S., Shipp, Margaret A., Rodig, Scott J.
Publicado em 2012

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013

Por Ribrag, Vincent, Armand, Phillippe, Kuruvilla, John, Michot, Jean-Marie, Moskowitz, Craig H, Marinello, Patricia, Snyder, Ellen, Balakumaran, Arun, Shipp, Margaret A, Zinzani, Pier Luigi
Publicado no J Immunother Cancer (2015)

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma

Por Pasqualucci, Laura, Compagno, Mara, Houldsworth, Jane, Monti, Stefano, Grunn, Adina, Nandula, Subhadra V., Aster, Jon C., Murty, Vundavally V., Shipp, Margaret A., Dalla-Favera, Riccardo
Publicado em 2006

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

Por Chen, Robert, Armand, Phillippe, Fanale, Michelle A, Ribrag, Vincent, Zinzani, Pier Luigi, Ricart, Alejandro D, Thompson, Seth, Balakumaran, Arun, Molin, Daniel, Shipp, Margaret A, Moskowitz, Craig H
Publicado no J Immunother Cancer (2015)

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms

Por Parekh, Samir, Polo, Jose M., Shaknovich, Rita, Juszczynski, Przemyslaw, Lev, Paola, Ranuncolo, Stella M., Yin, Yingnan, Klein, Ulf, Cattoretti, Giorgio, Favera, Riccardo Dalla, Shipp, Margaret A., Melnick, Ari
Publicado em 2007